Biology and Genetics

miR-26b-5p suppresses proliferation and promotes apoptosis in multiple myeloma cells by targeting JAG1. Jian CM et al. Pathol Res Pract. 2018 Sep. doi: 10.1016/j.prp.2018.07.025. [Epub 2018 Jul 27] Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activation‑dependent apoptosis. Zeng C et al. Oncol Rep. 2018 Sep. doi: 10.3892/or.2018.6544.…

Details

Myeloma UK publishes report on Patient Reported Outcome Measures (PROMs) in Myeloma

This month Myeloma UK published a new research report recommending that researchers, the NHS and healthcare professionals work together to improve the way that patient reported outcome measures (PROMs) are utilised in myeloma research. PROMs are questionnaires that are completed by patients and are often used either in a clinical trial setting to measure the impact of a…

Details

Prophylactic antibiotic combination reduces incidence of infection following ASCT

Results from a retrospective study have shown that prophylactic treatment with doxycycline and ciprofloxacin reduces the incidence of infection in myeloma patients following an autologous stem cell transplant (ASCT), when compared to treatment with ciprofloxacin alone. Published in Supportive Cancer Care, the results show that 53% of patients receiving ciprofloxacin alone developed neutropenic fever compared…

Details

Supportive treatments

Addition of doxycycline to ciprofloxacin for infection prophylaxis during autologous stem cell transplants for multiple myeloma. Sivik JM et al. Support Care Cancer. 2018 Mar 21. doi: 10.1007/s00520-018-4165-6. [Epub ahead of print]. Evaluation of the relevance of surgery in patients with multiple myeloma harboring symptomatic spinal involvement: a retrospective case series. Quidet M et al. World Neurosurg. 2018 Mar 9. pii: S1878-8750(18)30458-3. doi: 10.1016/j.wneu.2018.02.184.…

Details

Related conditions

Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. Katodritou E et al. Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6. Primary plasma cell leukemia in the era of novel agents for myeloma – a multicenter retrospective analysis of outcome. Ganzel C et…

Details

General

The impact of the introduction of bortezomib on dialysis independence in multiple myeloma patients with renal impairment: a nationwide Dutch population-based study. Oortgiesen BE et al. Haematologica. 2018 Mar 15. pii: haematol.2017.184754. doi: 10.3324/haematol.2017.184754. [Epub ahead of print]. Multiple Myeloma Presenting as a Superscan on 68Ga-Pentixafor PET/CT. Pan Q et al. Clin Nucl Med. 2018 Mar 13. doi: 10.1097/RLU.0000000000002067. [Epub ahead of…

Details

Diagnostic techniques and prognostic indicators

Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts. Marinac CR et al. Br J Cancer. 2018 Mar 12. doi: 10.1038/s41416-018-0010-4. [Epub ahead of print]. Multidrug resistance 1 (MDR1/ABCB1) gene polymorphism (rs1045642 C > T) and susceptibility to multiple myeloma: a systematic review and meta-analysis. Razi B et al. Hematology. 2018 Mar 1:1-7. doi: 10.1080/10245332.2018.1443897.…

Details

Current treatments

Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment: a retrospective study by the SFGM-TC. Augeul-Meunier K et al. Bone Marrow Transplant. 2018 Mar 9. doi: 10.1038/s41409-018-0122-8. [Epub ahead of print]. The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation…

Details

Complications of myeloma and its treatments

Calcified Alveolar Septal Pulmonary Amyloidosis as an Initial Manifestation of Multiple Myeloma. Kevorkof GV et al. Arch Bronconeumol. 2018 Mar 5. pii: S0300-2896(18)30020-6. doi: 10.1016/j.arbres.2018.01.005. [Epub ahead of print]. Severe pembrolizumab-associated neutropenia after CD34+ selected allogeneic hematopoietic-cell transplantation for multiple myeloma. Bryant AR et al. Bone Marrow Transplant. 2018 Mar 7. doi: 10.1038/s41409-018-0142-4. [Epub ahead of print]. Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management,…

Details